Additional file 2: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, , Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, , Haruhiro Saito, Tetsuro Kondo, Yukio Hosomi, Yoshiro Nakahara, Masanori Nishikawa, Keiko Utumi, Yuki Misumi, , Kentaro Sakamaki & Hiroaki Okamoto
Table S1. CEC data and treatment efficacy of 35 patients whose CEC count was measured on days 1 and 8. Abbreviations: EGFR, epidermal growth factor receptor; CEC, circulating endothelial cell; PR, partial response; SD, stable disease; PFS, progression-free survival; OS, overall survival. (DOCX 22Â kb)
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.